The association of HLA A1, B8, and DR3 with generalized myasthenia gravis (GMG) in Caucasoids is well established, but no particular gene has been implicated and there is still no adequate explanation in functional terms. In this study we have taken advantage of sequential genomic markers between B8 and DR3 so as to map the location of susceptibility gene(s) on the A1, B8, DR3 (8.1) ancestral haplotype. By studying 51 patients, we have delineated a region between HLA B and TNF which is shared by 29/29 patients with B8 and DR3, 19/19 patients with B8 but not DR3 and 2/3 patients with DR3 but not B8. The potential importance of this region was confirmed by examining a similar disease induced by D-Penicillamine (D-PenMG) and associated with different HLA class II alleles (DR1 and/or DR7). Among these patients, 7/16 (44%) have B8, often with other markers of 8.1. These results implicate at least two categories of genes in determining susceptibility to MG; one located in the region between HLA B and TNF may be immunoregulatory, whereas the second, located in the class II region, may relate to the inducing factor (e.g., DR1 or DR7 in D-PenMG).
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/BF00179791 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Association Between Primary Sclerosing Cholangitis and Microscopic Colitis: A Systematic Review.
Cureus
December 2024
Internal Medicine, Wayne State University School of Medicine, Dearborn, USA.
The association between primary sclerosing cholangitis (PSC) and microscopic colitis (MC) has been explored in limited studies, suggesting potential shared pathophysiological mechanisms. This systematic review aimed to investigate this relationship by analyzing studies identified through comprehensive searches in PubMed, Embase, and the Cochrane Library. Two studies met the inclusion criteria: a case series of 12 patients and a case report, collectively analyzing 13 cases.
View Article and Find Full Text PDFRedosing with Intralymphatic GAD-Alum in the Treatment of Type 1 Diabetes: The DIAGNODE-B Pilot Trial.
Int J Mol Sci
January 2025
Division of Pediatrics, Department of Biomedical and Clinical Sciences, Faculty of Medicine and Health Sciences, Linköping University, 581 83 Linköping, Sweden.
Immunotherapies aimed at preserving residual beta cell function in type 1 diabetes have been successful, although the effect has been limited, or raised safety concerns. Transient effects often observed may necessitate redosing to prolong the effect, although this is not always feasible or safe. Treatment with intralymphatic GAD-alum has been shown to be tolerable and safe in persons with type 1 diabetes and has shown significant efficacy to preserve C-peptide with associated clinical benefit in individuals with the human leukocyte antigen DR3DQ2 haplotype.
View Article and Find Full Text PDFCOVID-19 infection and inactivated vaccination: Impacts on clinical and immunological profiles in Chinese children with type 1 diabetes.
World J Diabetes
December 2024
Department of Pediatric Endocrinology and Inherited Metabolic Diseases, National Children's Medical Center, Children's Hospital of Fudan University, Shanghai 201102, China.
Background: The coronavirus disease 2019 (COVID-19) pandemic has been linked to an increased incidence of diabetes and diabetic ketoacidosis (DKA). However, the relationship between COVID-19 infection and progression to type 1 diabetes (T1D) in children has not been well defined.
Aim: To evaluate the influence of COVID-19 infection and inactivated vaccine administration on the progression of T1D among Chinese children.
Genetic Discovery and Risk Prediction for Type 1 Diabetes in Individuals Without High-Risk HLA-DR3/DR4 Haplotypes.
Diabetes Care
February 2025
Department of Pediatrics, University of California, San Diego, La Jolla, CA.
Article Synopsis
- The study investigates type 1 diabetes (T1D) in patients without high-risk HLA-DR3 or -DR4 haplotypes, identifying genetic factors and improving risk prediction for this group.
- Researchers analyzed data from 12,316 non-DR3/DR4 individuals, discovering 18 T1D risk variants that affect disease development differently based on HLA status and showing a greater polygenic burden for non-DR3/DR4 patients.
- A newly developed genetic risk score (GRS) significantly outperformed existing scores in predicting T1D for those without DR3/DR4, highlighting the need for tailored approaches in understanding and predicting the disease.
In silicon desinging of RANKL-targeting vaccine for protection of osteoporosis based on the epitope of Denosumab.
Int Immunopharmacol
January 2025
Orthopaedic Centre, The University of Hong Kong Shenzhen Hospital, Shenzhen, Guangdong 518000, China. Electronic address:
Background: Life quality of osteoporosis patients is affected significantly due to the severely complications of fracture and pain. RANKL, indicated as the key mediator of osteoporosis, plays a pathogenic role of osteoclasts induction. To target this program, two medications, bisphosphonate and Denosumab, were developed and achieved remarkable advantages in clinics.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!